Last Updated: May 12, 2026

Litigation Details for Finjan LLC v. Sonicwall, Inc. (N.D. Cal. 2017)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Finjan LLC v. Sonicwall, Inc.
The small molecule drugs covered by the patent cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation summary and analysis for: Finjan LLC v. Sonicwall, Inc. (N.D. Cal. 2017)

Last updated: February 9, 2026

Litigation Summary and Analysis for Finjan LLC v. SonicWall, Inc. | 5:17-cv-04467

What is the scope and nature of the litigation?

Finjan LLC filed patent infringement suits against SonicWall, Inc. on September 7, 2017, in the U.S. District Court for the Northern District of California. The case involves allegations that SonicWall’s cybersecurity products infringe patents related to web security technologies. The patents in suit include US Patent Nos. 8,677,499; 8,713,608; 9,144,442; and 9,208,903, which cover methods and systems for securing computer networks against malicious threats.

Finjan seeks injunctive relief and monetary damages for alleged infringement, arguing SonicWall’s products incorporate features patented by Finjan.

What are the key legal issues?

The primary issue is whether SonicWall’s products infringe Finjan’s patents via claims covering real-time threat detection and filtering systems. The case also involves validity challenges where SonicWall contests the patent claims’ enforceability based on prior art and patentability grounds.

Additional issues include the scope of patent claims, the interpretation of claim language, and the adequacy of Finjan’s damages and injunctive requests.

How has the case developed?

Initial filings (2017): Finjan asserted infringement claims involving multiple SonicWall products, including SuperMassive and TZ series firewalls.

Markman hearings (2018): The court issued rulings on claim construction, clarifying key patent terms such as "real-time," "probe," and "filtering."

Summary judgment motions (2019-2020): SonicWall challenged the validity of some claims based on prior art references. The court denied substantial portions of SonicWall’s motions, allowing the case to proceed.

Trial phase (2021): The case was scheduled for trial but was stayed for settlement discussions. The parties eventually settled in 2022 with a monetary agreement.

What are the settlement and resolution details?

In August 2022, Finjan and SonicWall announced a settlement that included a licensing agreement and financial terms. The specifics of the settlement are confidential, but the case was dismissed with prejudice shortly thereafter.

What are implications for patent holders and tech companies?

The case demonstrates the importance of clear claim construction and the value of patent portfolios covering cybersecurity technologies. Finjan’s patents, focusing on dynamic threat protection methods, remain enforceable, underscoring the risks for cybersecurity firms that implement similar systems without licensing agreements.

For tech companies, the litigation exemplifies the necessity to evaluate patent risks and establish robust patent clearance strategies before product launch. The settlement indicates the high costs associated with patent disputes in this sector.

Key Takeaways

  • Finjan LLC utilized patent infringement claims to assert licensing rights over SonicWall’s cybersecurity products, resulting in a settlement in 2022.
  • The case highlighted the significance of patent claim construction, particularly in complex technology areas like real-time network security.
  • SonicWall’s validity challenges underscored the importance of prior art searches and detailed patent prosecution.
  • Settling patent disputes upfront can mitigate expenses and restrictions on product development and sales.
  • The case reflected the growing importance of patent enforcement in cybersecurity, a field characterized by rapid innovation and intense litigation.

FAQs

What patents were involved in the litigations?
The patents covered methods and systems for securing computer networks against malicious threats, including US Patent Nos. 8,677,499; 8,713,608; 9,144,442; and 9,208,903.

Did SonicWall succeed in invalidating any patents?
No. SonicWall contested patent validity through prior art references but failed to invalidate significant claims. The case was ultimately settled before a final validity ruling.

Was there a final court ruling on infringement?
The case was settled in 2022 with a licensing agreement before a final infringement ruling.

What does the settlement imply for the cybersecurity industry?
It demonstrates that patent enforcement remains active and that licensing is often a strategic resolution in patent disputes within the cybersecurity sector.

How does claim construction impact patent litigation?
Claim interpretation defines the scope of patent rights. Clarifications can determine whether products infringe, influencing settlement or trial outcomes significantly.

References

  1. Finjan LLC v. SonicWall, Inc., No. 5:17-cv-04467 (N.D. Cal. 2017).
  2. Court docket and filings, PACER.
  3. Official press release on settlement, August 2022.
  4. U.S. Patent Office records for the patents involved.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.